Evidence map›Paper›PMID 40103457›Full record

ArticleCurrent cancer drug targets2026

YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas.

Miao Wang, Siyu Qian, Yue Zhang, Qingjiang Chen, Xudong Zhang, Mingzhi Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miao WangDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
Siyu QianDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
Yue ZhangDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
Qingjiang ChenDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
Xudong ZhangDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionYippee Like 1 (YPEL1) is a nuclear protein involved in various cellular processes, including cell cycle regulation, senescence, and mammalian development. It plays a dual role in cancer, functioning as either an antitumor or tumor-promoting factor.

methodsWe assessed the RNA and protein levels of YPEL1 in both NK/T-cell, lymphoma cell lines and gemcitabine-resistant lymphoma cells using qPCR and western blot, respectively. Flow cytometry was employed to analyze cellular apoptosis and the cell cycle. The impact of YPEL1 knockdown on the proliferation of NK/T-cell lymphoma cells was evaluated through CCK8 assay and a xenograft model, while transcriptomic analysis was conducted to explore the cellular signaling pathways influenced by YPEL1 silencing.

resultsIn the current study, via The Cancer Genome Atlas (TCGA) search, we found that YPEL1 is aberrantly expressed in various cancers. High expression of YPEL1 correlated with poorer survival outcomes, whereas low expression of YPEL1 was associated with improved overall survival of patients. YT cell lines and gemcitabine-resistant YT cell line (YT/Gem-R) exhibit elevated levels of the YPEL1 protein Conclusion: These findings suggest that YPEL1 exhibits the potential for being used as a target for NK / T cell lymphoma treatment.

Indexed as

Antimetabolites, AntineoplasticDeoxycytidineDrug Resistance, NeoplasmLymphoma, Extranodal NK-T-CellLymphoma, T-CellAnimalsApoptosisCell Line, TumorCell ProliferationFemaleGemcitabineGene Expression Regulation, NeoplasticHumansMiceXenograft Model Antitumor AssaysAntimetabolites, AntineoplasticDeoxycytidineGemcitabineapoptosiscancertumorYPEL1; YTYT/Gem-R

Identifiers

PMID40103457
PMCPMC13678611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.